Compare LQDA & MTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | MTDR |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2020 | 2011 |
| Metric | LQDA | MTDR |
|---|---|---|
| Price | $78.03 | $49.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | $41.00 | ★ $63.07 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | $158,320,000.00 | ★ $3,696,277,000.00 |
| Revenue This Year | $278.87 | $7.15 |
| Revenue Next Year | $57.13 | $7.63 |
| P/E Ratio | $147.92 | ★ N/A |
| Revenue Growth | ★ 1031.18 | 5.46 |
| 52 Week Low | $11.85 | $37.14 |
| 52 Week High | $78.25 | $66.84 |
| Indicator | LQDA | MTDR |
|---|---|---|
| Relative Strength Index (RSI) | 75.44 | 36.21 |
| Support Level | $31.23 | $48.07 |
| Resistance Level | N/A | $49.85 |
| Average True Range (ATR) | 4.14 | 1.75 |
| MACD | 0.40 | -0.17 |
| Stochastic Oscillator | 91.55 | 17.14 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.